Press Room

12th Global Drug Delivery & Formulation Virtual Summit

Start
Monday, March 15, 2021 - 00:00
End
Wednesday, March 17, 2021 - 00:00
Location: online
Drug Delivery Formulation | Hovione

At Hovione we are constantly innovating to find better and more efficient ways of doing things.

Visit Hovione’s booth at the 12th Global Drug Delivery and Formulation Summit (DDF) and meet our team of experts.



Learn more about ASD-HIPROS – the most advanced and accurate screening platform able to identify the most efficient and stable Amorphous Solid Dispersion formulations by Spray Drying. Requiring as little as 5g of API and in just 6 weeks, this platform maximizes your chances of identifying a successful formulation, accelerating development towards commercial manufacturing and patient availability.

Schedule a meeting button | Hovione





Don’t miss our “Technology & Innovation” Session

Featured Speakers: Mafalda Paiva - Group Leader, R&D Analytical Development and João Henriques - Group Leader, R&D Drug Product Development

Title: Performance Enhancement Strategies for Low Solubility APIs – do more with less

Session Track: Technology & Innovation

Date: Wednesday, March 17, 2021

Time: 09:25AM – 10:00AM GMT

Abstract: The presentation will address the main challenges in the formulation of ASDs, highlighting the importance of integrated development and the synergies between pre-formulation and commercial manufacturing expertise. Mafalda and João will also be presenting ASD HIPROS, our new state-of-the-art, science-based development platform for ASDs.

Conference Website: httpss://www.ddfevent.com/ 

12th Global Drug Delivery & Formulation Virtual Summit | Hovione

 

 

Interested in turning your most difficult challenge into a successful solution?

 

 

Schedule a meeting with our experts

 





 

You might be interested in:









 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026